Compare MakeMyTrip Ltd (MMYT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? MakeMyTrip Ltd trades at $59.96 (market cap $5.78B), while Vertex Pharmaceuticals Incorporated trades at $526.3 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 23.2× MakeMyTrip Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| MMYT | VRTX | |
|---|---|---|
Market Cap | $5.78B | $134.25B |
Sector | Technology | Health |
52-Week High | $103.21 | $529.65 |
52-Week Low | $36.30 | $376.62 |
Enterprise Value | $6.44B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $60.30, down 1.0% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2027 earnings that beat expectations despite revenue headwinds, maintaining robust gross margins of 73.45%. Recent news highlights growth in hotels and packages segments offsetting air travel softness, with analyst consensus strongly bullish at 73% buy ratings.
The outlook remains positive with earnings momentum and diversified travel services driving growth, though elevated P/E ratio of 267 and geopolitical travel disruptions present risks. Institutional sentiment supports upside potential with 34% average price target, while balance sheet strength provides stability amid market volatility.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
